Stockreport

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Intra-Cellular Therapies Inc.  (ITCI) 
Last intra-cellular therapies inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations
PDF The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability pr [Read more]